FXN / Frataxin Polyclonal Antibody

FXN / Frataxin Polyclonal Antibody

Introducing the FXN Frataxin Polyclonal Antibody (E-AB-64104) by Dana Biosciences. This meticulously crafted antibody is designed to provide researchers with a reliable tool for the detection and analysis of frataxin, a crucial protein involved in the pathogenesis of Friedreich's ataxia.

The FXN Frataxin Polyclonal Antibody (E-AB-64104) exhibits exceptional specificity and sensitivity, enabling accurate identification and quantification of frataxin in various biological samples. With its high affinity and low background, this antibody ensures precise and reproducible results, facilitating comprehensive investigations into the role of frataxin in disease progression and therapeutic interventions.

Manufactured using state-of-the-art techniques, this polyclonal antibody guarantees consistent performance and batch-to-batch reproducibility. Its exceptional quality is further validated through rigorous quality control measures, ensuring optimal functionality and reliability in diverse experimental settings.

The FXN Frataxin Polyclonal Antibody (E-AB-64104) is compatible with a wide range of applications, including Western blotting, immunohistochemistry, and immunofluorescence. Its versatility allows for versatile utilization across various research disciplines, enabling comprehensive exploration of frataxin's involvement in cellular processes and disease mechanisms.

Dana Biosciences, renowned for its commitment to scientific excellence, offers this antibody as part of its comprehensive portfolio of cutting-edge research tools. With its unwavering dedication to quality and innovation, Dana Biosciences ensures that researchers can confidently pursue their scientific endeavors with utmost precision and reliability.

In summary, the FXN Frataxin Polyclonal Antibody (E-AB-64104) by Dana Biosciences is a highly reliable and versatile tool for the detection and analysis of frataxin. With its exceptional specificity, sensitivity, and compatibility with various applications, this antibody empowers researchers to unravel the intricate mechanisms underlying Friedreich's ataxia and explore potential therapeutic avenues.